Results 41 to 50 of about 23,706 (182)
Clinical and Applied Thrombosis/Hemostasis, 2020 The prothrombotic state in patients with atrial fibrillation (AF) is related to endothelial injury, the activation of platelets and the coagulation cascade.
Aleksandra Lenart-Migdalska MD +5 more
doaj +1 more source
BMC Cardiovascular Disorders, 2022 Background This study aimed to analyze associations between genetic variants and plasma concentrations along with clinical outcomes in dabigatran in patients with non-valvular atrial fibrillation (NVAF).
Zhu Zhu +7 more
doaj +1 more source
Massive Left Atrial Thrombosis Shortly After Radiofrequency Catheter Ablation: Implications of Reduced Flow Dynamics Detected by Four-Dimensional Flow Magnetic Resonance Imaging. [PDF]
J ArrhythmA large left atrial (LA) thrombus developed 5 days after repeated ablation for persistent atrial fibrillation despite uninterrupted anticoagulation. The thrombus formed at the previously ablated LA roof, where four‐dimensional flow magnetic resonance imaging later showed reduced regional flow velocity, suggesting that persistent local flow stagnation ...
Egashira K +4 more
europepmc +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed +7 more
wiley +1 more source
Dabigatran pharmacokinetics (PK).
, 2019 PK of dabigatran etexilate administrated by one dose of 10 mg/kg intraperitoneal. Plasma dabigatran (p-dabigatran) were measured in two healthy rats at each time point (n = 14).
Jens Peter Goetze (316975) +9 more
core +1 more source
Рациональная фармакотерапия в кардиологии, 2016 Application of dabigatran etexilate for prevention of cardioembolic complications in nonvalvular atrial fibrillation is considered. Results of randomized clinical trials on efficacy and safety of dabigatran in various doses are discussed.
I. S. Yavelov
doaj +1 more source
BMC Cardiovascular Disorders, 2020 Background We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF) taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and bleeding risk.
Alexandros Briasoulis +7 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Dicloxacillin is a penicillinase‐resistant beta‐lactam antibiotic and potent activator of the Pregnane X receptor (PXR), known to induce CYP2C9, CYP2C19, and CYP3A4 activity. Clinical data suggest it reduces anticoagulation in warfarin‐treated patients and increases the risk of thromboembolic events.
Chanan Shaul +5 more
wiley +1 more source
Scientific ReportsDabigatran acylglucuronide, an active metabolite of dabigatran, exhibits higher plasma concentrations and distinct anticoagulant effects compared to dabigatran, suggesting that it may play a more significant role in overall anticoagulant activity than ...
Jong-Min Kim +4 more
doaj +1 more source
Российский кардиологический журнал, 2020 Aim. To analyze clinical characteristics of patients with nonvalvular atrial fibrillation (AF) in the Russian population, enrolled in the GLORIA-AF registry phase 2, depending on the antithrombotic therapy received, and to assess the potential for ...
E. V. Shlyakhto +12 more
doaj +1 more source